Streetbeat News

BSEM

BioStem Technologies Inc

https://www.biostemtechnologies.com/

CEO

Marc Barhonovich

Industry

Medicinal and Botanical Manufacturing

Open

13.75

Mkt cap

216M

Volume

5.4K

High

13.75

P/E Ratio

-18.07

52-wk high

28.26

Low

13.19

Div yield

N/A

52-wk low

4.41

Kane Biotech has announced a change in its US distribution partner for its revyve™ Antimicrobial Wound Gel. BioStem Technologies has signed a letter of intent to acquire exclusive US distribution rights for revyve™ from ProgenaCare Global.

Portfolio Pulse from

November 27, 2024 | 1:45 pm

BioStem Technologies Inc. has signed a Letter of Intent to acquire wound care products and technologies from ProgenaCare Global. This acquisition aims to enhance BioStem's portfolio in the advanced wound care market.

Portfolio Pulse from

November 20, 2024 | 12:15 pm

BioStem Technologies has signed a letter of intent to acquire wound care products and technologies from ProgenaCare Global, including ProgenaMatrix® and revyve™ Antimicrobial Wound Gel. This acquisition is part of BioStem's strategy to expand its commercial product portfolio.

Portfolio Pulse from

November 20, 2024 | 12:15 pm

BioStem Technologies has shown significant price volatility due to positive news and uplisting plans. Despite recent profit-taking, the Q3 earnings report revealed record revenue and positive net income, indicating strong financial performance. The company's future growth is promising with a robust product pipeline and potential Nasdaq uplisting, supporting a one-year price target of $27.88.

Portfolio Pulse from

November 15, 2024 | 2:30 pm

BioStem Technologies, Inc. (BSEM) held its Q3 2024 earnings call, discussing financial performance and company updates.

Portfolio Pulse from

November 15, 2024 | 12:00 pm

BioStem Technologies, Inc. reported a record third quarter 2024 revenue of $82.6 million, highlighting its strong performance in the MedTech sector.

Portfolio Pulse from

November 12, 2024 | 12:45 pm

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) and BioStem Technologies, Inc. (OTC:BSEM) have announced an agreement where NovaBay has been granted the right to commercialize BioStem Technologies' Amniotic Tissue Allograft. The product is intended for use as a protective covering during the repair of ocular surfaces.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.